

19



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

11 Publication number:

**0 073 657**  
**A1**

12

# EUROPEAN PATENT APPLICATION

21 Application number: 82304513.3

51 Int. Cl.<sup>3</sup>: **C 12 N 15/00, A 61 K 39/29**

22 Date of filing: 26.08.82

30 Priority: 31.08.81 US 298236

71 Applicant: **GENENTECH, INC.**, 460 Point San Bruno Boulevard, So. San Francisco California 94080 (US)

43 Date of publication of application: 09.03.83  
Bulletin 83/10

72 Inventor: **Hitzeman, Ronald A.**, 1251 Rosita, Pacifica California 94044 (US)  
Inventor: **Levinson, Arthur D.**, 2931 Frontera Way, Burlingame California 94010 (US)  
Inventor: **Yansura, Daniel G.**, 125 Ploche, San Francisco California 94134 (US)

84 Designated Contracting States: **AT BE CH DE FR GB IT LI LU NL SE**

74 Representative: **Armitage, Ian Michael et al, MEWBURN ELLIS & CO.** 2/3 Cursitor Street, London EC4A 1BQ (GB)

54 Preparation of hepatitis B surface antigen in yeast.

57 The hepatitis B surface antigen (HBsAg) for use in hepatitis vaccine is produced in particle form (like the natural product) by yeast transformed with a vector. The use of yeast has advantages over prokaryotic hosts, e.g. in yields.

A preferred vector is plasmid pYeHBs. This includes: a promoter derived from the yeast PKG promoter region; a **LEU2** gene allowing for selection in yeast; and the HBsAg gene. This last was derived from a plasmid containing the complete HBV gene inserted into the EcoRI site of pBH322.

**EP 0 073 657 A1**

-1-

PREPARATION OF HEPATITIS B SURFACE ANTIGEN IN YEAST

5 This invention relates to the use of recombinant DNA technology  
for the production of hepatitis B surface antigen (HBsAg) in  
yeast organisms for use in the preparation of vaccines against  
hepatitis B virus (HBV). In one aspect, the present invention  
relates to the construction of microbial expression vehicles  
10 containing DNA sequences encoding hepatitis B surface protein  
antigens operably linked to expression effecting promoter  
systems and to the expression vehicles so constructed. In  
another aspect, the present invention relates to yeast

-2-

organisms transformed with such expression vehicles, thus directed in the expression of the DNA sequences referred to above. In yet other aspects, this invention relates to the means and methods of converting the end products of such yeast  
5 expression to entities, such as vaccines, useful against hepatitis B virus. In preferred embodiments, this invention provides for particular expression vectors that utilize potent yeast promoters and DNA sequences distal to that encoding the hepatitis B surface antigen protein which, in combination,  
10 provide attractive yields of desired protein, produced in particle form of about 22 nm, and containing antigenic determinant(s) of hepatitis B virus.

The publications and other materials hereof used to illuminate the background of the invention, and in particular  
15 cases, to provide additional details respecting its practice are incorporated herein by reference, and for convenience, are numerically referenced in the following text and grouped in the appended bibliography.

20

#### Hepatitis B Virus

Hepatitis B (serum hepatitis) virus is transmitted among  
25 humans and manifests as chronically debilitating infections which can result progressively in severe liver damage, primary carcinoma and death. In most cases, complete recovery from hepatitis B infections can be expected; however, large segments of the population, especially in  
30 many African and Asian countries, are chronic carriers with the dangerous potential of transmitting the disease pandemically.

Hepatitis is caused by a virus vector (hepatitis B virus or HBV) which in its whole state - the so-called Dane particle-represents the virion and consists of a 27nm nucleocapsid enclosing a DNA molecule and an envelope surrounding the nucleocapsid. Proteins associated with the virion include the core antigen (HBcAg), a DNA polymerase and the surface antigen (HBsAg) which has been found in serum of infected and carrier humans. Antibodies to HBsAg have also been found in serum HBV infected people. It is believed that HBsAg is the HBV antigen that can induce immunogenic production of antibody (anti-HBs) and thus it would be the principal in an HBV vaccine. Attention is directed to: Dane et al., Lancet 1970 (1), 695 (1970); Hollinger et al., J. Immunology 107, 1099 (1971); Ling et al., J. Immunology 109, 834 (1972); Blumberg, Science 197, 17 (1977); Peterson et al., Proc. Nat. Acad. Sci (USA) 74, 1530 (1977) and Viral Hepatitis, A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention. (Vyas et al., eds.) Franklin Institute Press, Philadelphia, 1978, each of which is hereby incorporated by this reference to further illustrate the background of this invention.

HBsAg is present in infected plasma predominantly in the form of spherical particles having diameters ranging from about 16 to 25 nm -- the so-called "22 nm particle." These are thought to represent a noninfectious viral envelope. Because antibodies against HBsAg are protective against HBV infection, these non-infectious particles can effectively be used as a vaccine.

-4-

Inasmuch as the hepatitis B virus has not been infectious in cell culture and can only be obtained from infected humans or higher primates, means have not been available for obtaining and maintaining sufficient supplies of HBV for use in producing antigen for immunization against HBV.

The present invention provides the means and methods for producing a vaccine effective against HBV. By means of recombinant DNA technology, the gene encoding HBsAg was inserted together with appropriate translational start and stop signals under the control of an appropriate expression promoter into a replicable expression vector and the latter used to transform yeast cells. The cells, thus genetically directed, produced HBsAg directly and in particle form which, when purified, is suitable to immunize against HBV.

#### Recombinant DNA Technology

With the advent of recombinant DNA technology, the controlled microbial production of an enormous variety of useful polypeptides has become possible. Many mammalian polypeptides, such as human growth hormone and leukocyte interferons, have already been produced by various microorganisms. The power of the technology admits the microbial production of an enormous variety of useful polypeptides, putting within reach the microbially directed manufacture of hormones, enzymes, antibodies, and vaccines useful against a wide variety of drug-targeting applications.

A basic element of recombinant DNA technology is the plasmid, an extrachromosomal loop of double-stranded DNA

-5-

found in bacteria oftentimes in multiple copies per cell. Included in the information encoded in the plasmid DNA is that required to reproduce the plasmid in daughter cells (i.e., a "replicon" or origin of replication) and  
5 ordinarily, one or more phenotypic selection characteristics, such as resistance to antibiotics, which permit clones of the host cell containing the plasmid of interest to be recognized and preferentially grown in selective media. The utility of bacterial plasmids lies in  
10 the fact that they can be specifically cleaved by one or another restriction endonuclease or "restriction enzyme", each of which recognizes a different site on the plasmid DNA. Thereafter heterologous genes or gene fragments may be inserted into the plasmid by endwise joining at the  
15 cleavage site or at reconstructed ends adjacent to the cleavage site. Thus formed are so-called replicable expression vehicles.

DNA recombination is performed outside the microorganism,  
20 and the resulting "recombinant" replicable expression vehicle, or plasmid, can be introduced into microorganisms by a process known as transformation and large quantities of the recombinant vehicle obtained by growing the transformant. Moreover, when the gene is properly inserted  
25 with reference to portions of the plasmid which govern the transcription and translation of the encoded DNA message, the resulting expression vehicle can be used to direct the production of the polypeptide sequence for which the inserted gene codes, a process referred to as expression.

30

Expression is initiated in a DNA region known as the promoter. In the transcription phase of expression, the DNA

-6-

unwinds exposing it as a template for initiated synthesis of messenger RNA from the DNA sequence. The messenger RNA is, in turn, bound by ribosomes, where the messenger RNA is translated into a polypeptide chain having the amino acid sequence encoded by the mRNA. Each amino acid is encoded by a nucleotide triplet or "codon" which collectively make up the "structural gene", i.e., that part of the DNA Sequence which encodes the amino acid sequence of the expressed polypeptide product. Translation is initiated at a "start" signal (ordinarily ATG, which in the resulting messenger RNA becomes AUG). So-called stop codons define the end of translation and, hence, the production of further amino acid units. The resulting product may be obtained by lysing the host cell and recovering the product by appropriate purification from other bacterial proteins.

In practice, the use of recombinant DNA technology can express entirely heterologous (not ordinarily found in, or produced by, a given micro-organism), polypeptides -- so-called direct expression -- or alternatively may express a heterologous polypeptide fused to a portion of the amino acid sequence of a homologous (found in, or produced by, the corresponding wild-type microorganism) polypeptide. In the latter cases, the intended bioactive product is sometimes rendered bioinactive within the fused, homologous/heterologous polypeptide until it is cleaved in an extracellular environment. See, eg., British Patent Publ. No. 2 007 676 A and Wetzel, American Scientist 68, 664, (1980).

If recombinant DNA technology is to fully sustain its promise, systems must be devised which optimize expression

of gene inserts, so that the intended polypeptide products can be made available in controlled environments and in high yields.

5

British Patent Publication 2034323A, published June 4, 1980, describes the isolation of the HBV genome comprising about 3200 nucleotides and the incorporation of  
10 this DNA into a vector taking advantage of an EcoRI digest and subsequent ligation. It is stated that the resultant cloned HBV-DNA can be labelled and used as a probe to detect Dane particles in serum and that the vector could be used to express a polypeptide containing a hepatitis B  
15 protein fragment.

In a related article from the same laboratories (Proc. Natl. Acad. Sci (USA) 77, 4549 (1980)), it is reported that  
20 tandem cloned hepatitis B genomes were introduced into mouse cells and integrated into the mouse chromosome. Polypeptide identified as hepatitis surface antigen was excreted from the cells as particles similar to those found in the sera of infected humans.

25 European Patent Application Publication No. 13828 describes the production of HBV core antigen by read-through translation of an mRNA transcript from the genomic DNA. No surface antigen was detected.

30 In European Patent Application Publication No. 20251 there is described the production in E. coli of a fusion protein purportedly containing a portion of the surface antigen



protein of HBV. Because the surface antigen determinants were present as a fusion protein, the structure could not be native; hence, the reported low immunological activity.

5

The present invention is based upon the discovery that recombinant DNA technology can be used to successfully and efficiently produce the hepatitis B surface antigens, directly and in discrete particle form. The product is suitable for use in conferring immunogenicity to hepatitis B virus in a susceptible human or for preparing a vaccine for such use. The product is produced in a eukaryotic host - yeast - and thus carries the advantages such systems confer on corresponding, proteinaceous products, to wit, glycosylation and sugar and lipid association more closely related to human produced proteins versus bacterial produced proteins whose hosts are incapable of such sophisticated processing. In addition, the eukaryotic yeast cells tolerate the protein product better than prokaryotic systems, doubtless increasing expression levels and yields significantly over bacterial systems, in which the hepatitis protein per se proved lethal.

The present invention comprises the hepatitis B surface antigen (HBsAg) produced and the methods and means of its production. Specifically, the present invention is directed to HBsAg in particle form comprising immunogenic determinant(s) of hepatitis B virus, produced in yeast. The HBsAg hereof is produced in discrete particle form, devoid of any additional, fused polypeptide artifact, whether encoded by another portion of the HBV genome or by DNA homologous to the yeast strain employed. The present invention is further directed to

-9-

replicable DNA expression vehicles harboring gene sequences encoding HBsAg in directly expressible form. Further, the present invention is directed to yeast strains transformed with the expression vehicles described above and to microbial  
5 cultures of such transformed yeast strains, capable of producing HBsAg. In still further aspects, the present invention is directed to various processes useful in preparing said HBsAg gene sequences, DNA expression vehicles, yeast strains and cultures and to specific embodiments thereof.  
10 Still further, this invention is directed to the use of thus produced HBsAg for the preparation of vaccines useful to confer immunogenicity to HBV in susceptible humans, to such vaccines and to the method of using them to inoculate and confer immunogenicity to HBV in susceptible humans.

15

The preferred promoter herein is one tailored from the yeast 3-phosphoglycerate kinase (PGK) promoter region which is  
20 described infra. The PGK gene was analyzed for restriction sites which would be useful for sequencing. DNA sequence analysis around one of these restriction sites indicated that translation beginning with a specific ATG would yield a protein whose N-terminal amino acids corresponded to the same  
25 N-terminal amino acids of human and horse PGK, this flanking DNA being considered the yeast PGK promoter region. The PGK promoter region was analyzed for a region which would logically support a unique restriction site. A primer repair reaction was carried out and this unique site was placed at the 3' end  
30 of the PGK promoter region. This unique site allowed the PGK promoter region to effect the direct expression of the thus fused gene in yeast.

-10-

A yeast/bacteria shuttle plasmid, pCV13 (or YEpl3) described infra, had certain restriction fragments removed. Replacement of these fragments by PGK promoter region fused to surface antigen allowed reclosure of the vector. This vector was used to transform yeast which were grown up under customary fermentation conditions and permitted to produce the desired HBsAg product. Recovery of product followed by breaking open the transformed yeast. Supernatants from centrifuged solution were used as a substrate in hepatitis B surface antigen radioimmune assays.

A particular DNA sequence, found to be suitable herein as a transcription terminator, was placed after the gene sequence encoding HBsAg in order to terminate mRNA synthesis and provide a Poly A addition site for proper mRNA processing and translation. This terminator is based upon the 232bp Hind III-to-BglII restriction fragment from the Trp1 gene contained in pFRL4. This fragment was isolated containing some coding sequence from the yeast TRP1 gene and the 3'-flanking sequence required for proper transcription termination and polyadenylation. This terminator fragment was fused via its HindIII site to the HindIII site of the HBsAg gene. Transcription of the HBsAg gene by a fused yeast promoter in yeast is designed to terminate in the fused TRP1 terminator fragment.

pCV13(1) contains the ampicillin and tetracycline resistance genes allowing for plasmid selection in E. coli, an E. coli origin of DNA replication, the LEU2 gene allowing for selection of the plasmid in yeast and the 2 (micron) origin allowing for DNA replication of the plasmid in yeast. This plasmid is found in the nucleoplasm of transformed yeast. The

-11-

small HindIII-to-BamHI fragment from the tetracycline  
resistance gene was removed from the vector. The resulting  
large vector fragment was then ligated with the 1.6 kbp  
HindIII-to-EcoRI assembled PGK promoter fragment and a 1.1kbp  
5 EcoRI-to-BglII HBsAg/TRP1 terminator fragment so as to produce  
the pYcHBs vector in Figure 6. This HBsAg expression vector  
was constructed to have the PGK promoter fragment initiate  
transcription of the HBsAg structural gene and then terminate  
this transcript in the TRP1 terminator previously fused to the  
10 HBsAg gene.

Preferred embodiments of the invention will now be  
described in greater detail with reference to the  
accompanying drawings in which:  
Figure A depicts the construction of plasmid pSVR containing  
15 SV40 DNA with a deletion of the coding region for the VP-1  
protein.

Figure 1 schematically illustrates the restriction map of the  
3.1 kbp HindIII insert of vector pBI from which the PGK  
20 promoter was isolated. Indicated is the insertion of an EcoRI  
site and an XbaI site in the 5'-flanking DNA of the PGK gene.

Figure 2 illustrates the 5'-flanking sequence plus the initial  
coding sequence for the PGK gene before insertion of XbaI  
25 and EcoRI sites.

Figure 3 schematically illustrates techniques used to insert an  
XbaI site at position - 8 in the PGK promoter and to isolate a  
39bp fragment of the 5'-flanking sequence of PGK containing  
30 this XbaI end and a Sau3A end.

Figure 4 schematically illustrates the construction of a 300 bp  
fragment containing the above 39bp fragment, additional PGK  
5'-flanking sequence (265bp) from PvuI to Sau3A (see Fig. 1).

-12-

and a EcoRI site adjacent to XbaI.

Figure 5 schematically illustrates the construction of the 1500 bp PGK promoter fragment (HindIII/EcoRI) which contains, in addition to the fragment constructed in Fig. 4, a 1300bp HindIII to PvuI fragment from PGK 5'-flanking sequence (see Fig. 1).

Figure 6 schematically illustrates the construction of an expression vector for hepatitis surface antigen in yeast, containing the modified PGK promoter, the HBsAg gene, and the terminator region of the yeast TRP1 gene, as described in more detail herein.

Figure 7 depicts: A) sucrose gradient sedimentation of yeast produced HBsAg compared with 22 nm particle and B) a corresponding CsCl gradient centrifugation thereof.

#### Yeast Host Organisms

20

In the preferred embodiments hereof, the expression system was placed in the plasmid pCV13 (1), which is capable of selection and replication in both E. coli and yeast, Saccharomyces cerevisiae. For selection in yeast the plasmid contains the LEU2 gene (2) which complements yeast (allows for growth in the absence of leucine) containing mutations in this gene found on chromosomes III of yeast (3). The strain used here was the strain XY610-8C which has the genotype a leu2 trp1 ade6 ade2 lys1 can1. This strain is deposited in the American Type Culture Collection without restriction (ATCC No. 20622). However, it will be understood that any

-13-

Saccharomyces cerevisiae strain containing a mutation which makes the cell Leu2 should be an effective environment for expression of the plasmid containing the expression system. An example of another strain which could be used is ATCC No. 38626  
5 which has the genotype, a leu2-3 leu2-112 his4-519 can1 (4). This strain has two point mutations in leu2 which restricts reversion and allows for tighter transformation of Leu<sup>-</sup> to Leu<sup>+</sup>.

10 Yeast Promoters

The 5' - flanking DNA sequence from a yeast gene (for alcohol dehydrogenase 1) can promote the expression of a foreign gene (eg. leukocyte interferon D) when placed in a  
15 plasmid used to transform yeast. Another yeast gene has been placed at the 3' - end of this construction to allow for proper transcription termination and polyadenylation in yeast. Indeed, we have shown that the mRNA transcript does end (3'-end) as expected in the termination/adenylation region of  
20 the yeast TRP1 gene (Hitzeman et.al., Nature, 293, 717 (1981)). This promoter can be suitably employed in the present invention as well as others -- cf. infra. In the preferred embodiments, the 5'-flanking sequence of the yeast 3-phosphoglycerate kinase gene (5) was placed upstream from the structural sequence for  
25 hepatitis surface antigen followed again by DNA containing the TRP1 gene termination - polyadenylation signals.

Since both the yeast alcohol dehydrogenase I 5'-flanking sequence and the 3-phosphoglycerate kinase 5'-flanking sequence (infra) can function to promote expression of foreign genes in  
30 yeast, it seems likely that the 5'-flanking sequences of any highly-expressed yeast gene could be used for the expression of important gene products. Since under some

-14-

circumstances yeast expresses up to 65 percent of its soluble protein as glycolytic enzymes (6) and since this high level appears to result from the production of high levels of the individual mRNAs (7), it should be possible to use the

5 5'-flanking sequences of any other glycolytic genes for such expression purposes - e.g., enolase, glyceraldehyde - 3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose - 6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate

10 isomerase, phosphoglucose isomerase, and glucokinase. Any of the 3'-flanking sequences of these genes could also be used for proper termination and mRNA polyadenylation in such an expression system - cf. Supra. Some other highly expressed genes are those for the acid phosphatases (8) and those that

15 express high levels of production due to mutations in the 5'-flanking regions (mutants that increase expression) - usually due to the presence of a Ty1 transposon element (9).

All of the genes mentioned above are thought to be

20 transcribed by yeast RNA polymerase II (9). It is possible that the promoters for RNA polymerase I and III which transcribe ribosomal DNA, 5S DNA, and tRNA DNA (9, 10), may also be useful in such expression constructions.

25 Finally, many yeast promoters also contain transcriptional control so that they can be turned off or on by variation in growth conditions. Some examples of such yeast promoters are the genes that produce the following proteins: Alcohol dehydrogenase II, isocytochrome, acid phosphatase, degradative

30 enzymes associated with nitrogen metabolism, glyceraldehyde -3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization (9). Such a control region would be

-15-

very useful in controlling expression of protein products - especially when their production is toxic to yeast. It should also be possible to put the control region of one 5'-flanking sequence with a 5'-flanking sequence containing a promoter from  
5 a highly expressed gene. This would result in a hybrid promoter and should be possible since the control region and the promoter appear to be physically distinct DNA sequences.

#### Detailed Description

10

#### Identification of PGK Promoter DNA

The six N-terminal amino acids of the 3-phosphoglycerate enzyme purified from humans are as follows:

15

1 - 2 - 3 - 4 - 5 - 6  
SER - LEU - SER - HSM - LYS - LEU -

One of the translational reading frames generated from the  
20 DNA sequence of the 141 bp Sau3A-to-Sau3A restriction fragment (containing the internal HincII site; see PGK restriction map Figure 1) produces the following amino acid sequence.

1 - 2 - 3 - 4 - 5 - 6  
25 MET - SER - LEU - SER - SER - LYS - LEU -

After removal of initiator methionine, it is seen that PGK N-terminal amino acid sequence has 5 of 6 amino acid homology with N-terminal amino acid sequence of human PGK.

30

This sequencing result suggested that the start of the yeast PGK structural gene is coded for by DNA in the 141bp



Sau3A restriction fragment of pB1. Previous work (5) has suggested that the DNA sequences specifying the PGK mRNA may reside in this area of the HindIII fragment. Further sequencing of the 141 bp Sau3A fragment gives more DNA sequence  
5 of the PGK promoter (Shown in Figure 2).

Protocol: For the insertion of XbaI/EcoRI sites in the 5'-flanking sequence of the PGK gene and the Construction of a Promoter Fragment (see Fig. 1)

10

Step 1) Primer-repair reaction and cloning of 39bp XbaI-to Sau3A fragment (as shown in Fig. 3).

15

Step 2) Clone PvuI-to-XbaI partial promoter fragment (as shown in Fig. 4)

20

Step 3) Clone EcoRI-to-EcoRI promoter fragment (as shown in Fig. 5) - contains the HindIII-to-EcoRI promoter fragment used in Fig. 6 for construction of expression plasmid.

Insertion of EcoRI Restriction Site In the PGK Promoter and Promoter Reassembly

25

The use of the PGK promoter for direct expression of heterologous genes in yeast requires that there be a restriction site on the 3' end of the PGK promoter fragment which does not contain the PGK initiator ATG. Figures 1, 3, 4 and 5 show how we inserted an EcoRI site in the PGK promoter.  
30 We used a primer-repair reaction (11) to first insert an XbaI site in the 3' end of promoter sequence. This XbaI sticky end was ligated to the XbaI site of a LEIFA (12) gene containing an

EcoRI site adjacent to the XbaI site. This connection sequence at the 5' end of the LEIFA gene is as follows:

5'-TCTAGAATTCATG-3'  
3'-AGATCTTAAGTAC-5'

This connection on the LEIFA gene is how an EcoRI site was inserted next to the XbaI site on the PGK promoter. Use of this XbaI-to-EcoRI connection allows for placement of structural genes containing either of these restriction ends at the 3' end of the PGK promoter for expression purposes.

#### Construction of expression vector

##### 15 Isolation of HBsAg Structural Gene

The structural gene coding for the HBsAg was recovered from a plasmid (pHBV-T-1A) containing the entire genome of HBV cloned into the EcoRI site of pBR322. This clone was obtained by methods similar to those recently published by Valenzuela et. al. (14) and (15).

The structural gene was modified in two ways 1) to incorporate a unique restriction site directly in front of the initial ATG methionine codon and 2) to blunt-end ligate the HBV Hpa I site located distal to the HBsAg gene to the filled in EcoRI site of pBR322. These two modifications to the DNA fragment containing the HBsAg structural gene were accomplished as described below:

1.) 50 µg of pHBV-T-1A DNA was first digested with Hpa II (80 units) in 200 µl reaction mixture according to enzyme supplier's (BRL) reaction condition to obtain a 1.7 kb DNA fragment, in which the initiation codon for the coding

sequences of HBsAg was located close to the 5' end of the sense-strand (about 400 bp). The DNA was purified by electrophoresis on polyacrylamide gels. (PAGE). The purified HpaII fragment was then treated with  $\lambda$  exonuclease (2 units) in  
5 100  $\mu$ l reaction mixture (New England BioLab) for 30 minutes at 37°C.  $\lambda$  exonuclease is a 5' exonuclease which digests double stranded DNA. This reaction degraded the 5' half of the "sense-strand" DNA from HBsAg coding sequences and exposed the antisense strand for pairing with added primer. The  $\lambda$   
10 exonuclease treated DNA was deproteinized and resuspended in 50  $\mu$ l of reaction mixture containing 40 mM potassium phosphate buffer (pH 7.4), 1 mM DTT, 50  $\mu$ g/ml BSA, 6mM MgCl<sub>2</sub>, 0.5 mM each of dNTPs, and 0.2 n mole of dATGGAGAACATC- (<sup>32</sup>p-labelled at 5' end by polynucleotide kinase). The mixture was first heated at  
15 90°C for 1 minute, annealed at 0°C for 30 minutes and then incubated at 37°C for 3 hours in the presence of 2 units of E. coli DNA polymerase I Klenow fragment (16). The DNA polymerase synthesized DNA primed by the added primer and degraded single-stranded DNA with 3'-OH termini and, therefore,  
20 created blunt ended DNA molecules. The resultant DNA was then deproteinized, digested with XbaI (45 units) at a site located within the HBsAg gene in a 100  $\mu$ l reaction mixture and fractionated by PAGE. A 91 base pair DNA fragment containing the first 30 codons of HBsAg gene was isolated after  
25 autoradiographic detection (fragment A).

To create a unique restriction site site immediately 5' to the HBsAg gene, we took advantage of a derivative of the plasmid pBR322 (called pNCV) which contains a synthetic DNA segment with the sequence: AATTCTGCAG

30 GACGTCTTAA

located at the EcoRI site. Incorporated into this synthetic DNA sequence is a PstI site. Ten  $\mu$ g of pNCV DNA was first cut

with 24 units of PstI enzyme in a 100  $\mu$ l reaction mixture and then treated with 2 units E. coli DNA polymerase Klenow fragment in 50  $\mu$ l reaction mixture as described above at 8°C for 1 hour. The DNA polymerase treatment removed the 4  
5 base-pair 3' overhang created by PstI digestion to leave a blunt ended DNA with an intact EcoRI restriction site giving the fragment B, containing the origin of replication of pBR322. The blunt ended HBsAg gene fragment A prepared above was ligated to the EcoRI site of fragment B. This was  
10 accomplished in a three fragment ligation to create a plasmid pHS94. The third fragment (fragment C) was prepared as follows:

2.) The HBsAg gene from the plasmid pHBV-T-1A was cleaved with HpaI at a site distal to the HBsAg gene. The HpaI site was  
15 ligated to a EcoRI site of pBR322 previously filled in with DNA polymerase I Klenow fragment (16). This was accomplished by subcloning the derivative of pBR322 to give pHS42. This plasmid was cleaved with XbaI (which cleaves at codon 31) and with Bam HI (which cleaves 375 base pairs from the EcoRI site  
20 of pBR322) to give a DNA fragment containing most of the HBsAg gene, ca. 150 base pairs distal to the HBsAg gene, and the promotor/operator and the first 200 base pairs of the tetracycline resistance gene. The DNA fragment C, bounded by XbaI and BamHI was isolated by PAGE and used in the three  
25 fragment ligation described above to give the plasmid pHS94. (Fig. A).

Successful expression of a heterologous gene in yeast requires that transcription of that gene end with a sequence of  
30 DNA which allows for proper processing (polyadenylation) and transport of that transcript.

DNA RESTRICTION AND MODIFICATION ENZYMES

Restriction enzymes EcoRI and HindIII along with bacterial alkaline phosphatase were purchased from Bethesda Research Laboratories. DNA polymerase (Klenow fragment) was purchased from Boehringer-Mannheim.  $T_4$  polynucleotide kinase, ATP and the deoxynucleoside triphosphates dATP, dGTP, dCTP and dTTP were purchased from PL Biochemicals. All other DNA restriction and metabolic enzymes were purchased from New England Biolabs.  $[\gamma\text{-}^{32}\text{P}]\text{ATP}$  was purchased from Amersham Corp. DNA restriction and metabolic enzymes were used in conditions exactly described by their respective manufacturers.

DNA Preparation and Transformation

Purification of covalently closed circular plasmid DNAs from E. coli (17) and yeast (18) plus the transformation of E. coli (19) and yeast (20, 21) were performed as previously described. E. coli miniscreens were done as previously described (22).

Strains and Media

E. coli K-12 strain 294 (ATCC No. 31446) (23) was used for all bacterial transformations. Yeast strain XV610-8C having the genotype (leu2 trp1 ade6 and/or ade2, lys1 can1 was used as yeast cloning host. (ATCC No. 20622 ).

LB (rich) medium was prepared as described by Miller (24) with the addition of either 20  $\mu\text{g/ml}$  ampicillin (Sigma) or 20  $\mu\text{g/ml}$  tetracycline (Sigma).

-21-

Restriction Map and Partial Sequencing of 3.1 kbInsert of pBl

300  $\mu$ g of pBl(5) was exhaustively digested with HindIII in  
5 a 500 $\mu$ l reaction volume, then electrophoresed on a 1 percent  
agarose preparative agarose (Sea Kem) gel. The 3.1 kb HindIII  
insert was cut from the ethidium stained gel, electroeluted  
(25), 2x extracted with equal volumes of buffer-saturated  
phenol and chloroform before ethanol precipitation. Portions  
10 of the resuspended DNA fragment was divided up and subjected to  
restriction cuts with a group of different restriction enzymes  
to yield the partial restriction map depicted in Figure 1.

30  $\mu$ g of the purified 3.1 kb insert was cut with Sau3A then  
15 run on a 6 percent acrylamide gel. Fragments corresponding to  
the 265 bp and 141 bp were separately purified by electroelution  
as described above. Each DNA fragment was then subjected to  
DNA sequence analysis (25).

20 A portion of this DNA sequence is shown in Figure 2. Amino  
acids corresponding to the N-terminal amino acids of the PGK  
structural gene are printed above the DNA sequence.

Insertion of a Restriction Site in the PGK 5' Promoter Region

25

A synthetic oligonucleotide with the sequence  
5'ATTGTTGTAA3' was synthesized by standard methods (26).  
100 ng of this primer was labelled at the 5' end using 10 units  
of T4 polynucleotide kinase in a 20  $\mu$ l reaction also containing  
30 200  $\mu$ Ci of [ $\gamma$ <sup>32</sup>-P] ATP. This labelled primer solution was  
used in a primer-repair reaction designed to be the first step  
in a multi-step process to put an EcoRI restriction site in the

PGK 5'-flanking DNA just preceding PGK structure gene sequence. The multistep process is explained below:

Step 1 (Figure 3)

5

Primer repair reactions and  
cloning of 39bp XbaI-to-Sau3A PGK piece

100  $\mu$ g of pBI was completely digested with HaeIII then run  
10 on a 6 percent polyacrylamide gel. The uppermost band on the  
ethidium stained gel (containing PGK promoter region) was  
isolated by electroelution as described above. This 1200 bp  
HaeIII piece of DNA was restricted with HindII then run on a  
6 percent acrylamide gel. The 650 bp band was isolated by  
15 electroelution. 5  $\mu$ g of DNA was isolated. This 650 bp  
HaeIII-to-HindII piece of DNA was resuspended in 20  $\mu$ l dH<sub>2</sub>O,  
then mixed with the 20  $\mu$ l of the phosphorylated primer solution  
described above. This mixture was 1X phenol-chloroform  
extracted then ethanol precipitated. Dried DNA was resuspended  
20 in 50  $\mu$ l of H<sub>2</sub>O and then heated in a boiling water bath for  
seven minutes. This solution was then quickly chilled in a dry  
ice-ethanol bath (10-20 seconds) then transferred to an  
ice-water bath. To this solution was added 50  $\mu$ l of a solution  
containing 10  $\mu$ l of 10X DNA polymerase I buffer (Boehringer  
25 Mannheim), 10  $\mu$ l of a solution previously made 2.5mM in each  
deoxynucleoside triphosphate (dATP, dTTP, dGTP and dCTP), 25  $\mu$ l  
of dH<sub>2</sub>O and 5 units of DNA Polymerase I, Klenow fragment.  
This 100  $\mu$ l reaction was incubated at 37°C for 4 hours. The  
solution was then 1X phenol-chloroform extracted, ethanol  
30 precipitated, dried by lyophilization then exhaustively  
restricted with 10 units of Sau3A. This solution was then run

on a 6 percent acrylamide gel. The band corresponding to 39 bp in size was cut from the gel then isolated by electroelution, as described above. This 39 bp band has one blunt end and one Sau3A sticky end. This fragment was cloned into a modified

5 pFIFtrp69 vector (11). 10  $\mu$ g of pFIFtrp69 was linearized with XbaI, 1X phenol chloroform extracted, then ethanol precipitated. The XbaI sticky end was filled in using DNA Polymerase I Klenow fragment in a 50  $\mu$ l reaction containing 250  $\mu$ M in each nucleoside triphosphate. This DNA was cut with

10 BamHI then run on a 6 percent acrylamide gel. The vector fragment was isolated from the gel by electroelution then resuspended in 20  $\mu$ l dH<sub>2</sub>O. 20 ng of this vector was ligated with 20 ng of the 39bp fragment synthesized above for 4 hours at room temperature. One-fifth of the ligation mix was used to

15 transform E. coli strain 294 to ampicillin resistance (on LB +20  $\mu$ g/ml amp plates. Plasmids from the transformants were examined by a quick screen procedure (22). One plasmid, pPGK-39 was selected for sequence analysis. 20  $\mu$ g of this plasmid was digested with XbaI, ethanol precipitated then

20 treated with 1000 units of bacterial alkaline phosphatase at 58°C for 45 min. The DNA was 3X phenol-chloroform extracted, then ethanol precipitated. The dephosphorylated ends were then labeled in a 20  $\mu$ l reaction containing 200  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P] ATP and 10 units of T<sub>4</sub> polynucleotide kinase. The plasmid was

25 cut with SalI and run on a 6 percent acrylamide gel.

The labeled insert band was isolated from the gel and sequenced by the chemical degradation method (25). The DNA sequence at the 3'-end of this promoter piece was as expected.



## Step 2 (Figure 4)

Construction of 312 bp PvuI-to-EcoRI PGK Promoter Fragment

5        25 µg of pPGK-39 (Fig. 3) was simultaneously digested with  
         SalI and XbaI (5 units each) then electrophoresed on a 6  
         percent gel. The 390 bp band containing the 39 bp promoter  
         piece was isolated by electroelution. The resuspended DNA was  
         restricted with Sau3A then electrophoresed on an 8 percent  
10       acrylamide gel. The 39 bp PGK promoter band was isolated by  
         electroelution. This DNA contained 39 bp of the 5' end of the  
         PGK promoter on a Sau3A-to-XbaI fragment.

         25 µg of pBI was restricted with PvuI and KpnI then  
15       electrophoresed on a 6 percent gel. The .8 kbp band of DNA was  
         isolated by electroelution, then restricted with Sau3A and  
         electrophoresis on a 6 percent gel. The 265 bp band from the  
         PGK promoter (Figure 1) was isolated by electroelution.

         This DNA was then ligated with the 39 bp promoter fragment  
20       from above for two hours at room temperature. The ligation mix  
         was restricted with XbaI and PvuI then electrophoresed on a  
         6 percent acrylamide gel. The 312 bp XbaI-to-PvuI restriction  
         fragment was isolated by electroelution, then added to a  
         ligation mix containing 200 ng of pBR322 [previously  
25       isolated missing the 162 PvuI-to-PstI restriction fragment] and  
         200 ng of the XbaI-to-pst I LeIFA cDNA gene previously isolated  
         from 20 µg of pLEIFtrpA. This 3-factor-ligation mix was used  
         to transform E. coli strain 294 to tetracycline resistance.  
         Transformant colonies were miniscreened and one of the colonies,  
30       pPGK-300 was isolated as having 304 bp of PGK 5'-flanking DNA  
         fused to the LeIFA gene in a pBR322 based vector. The 5' end  
         of the LeIFA gene has the following sequence: 5'-CTAGAAATTC

-25-

3', thus fusion of the XbaI site from the PGK promoter fragment into this sequence allows for the addition to the XbaI site an EcoRI site. pPGK-300 thus contains part of the PGK promoter isolated in a PvuI-to-EcoRI fragment.

5

Step 4 (Fig. 5)

Construction of a 1500 bp EcoRI-to-EcoRI PGK Promoter Fragment

10        10  $\mu$ g of pB1 was digested with PvuI and EcoRI and run on a 6 percent acrylamide gel. The 1.3 kb PvuI-to-EcoRI DNA band from the PGK 5'-flanking DNA was isolated by electroelution. 10  $\mu$ g of pPGK-300 was digested with EcoRI and PvuI and the 312 bp promoter fragment was isolated by electroelution after  
15 electrophoresing the digestion mix on a 6 percent gel. 5  $\mu$ g of pFRL4 was cut with EcoRI, ethanol precipitated then treated with bacterial alkaline phosphatase at 68° for 45 minutes. After 3X phenol/chloroform treating the DNA, ethanol precipitation, and resuspension in 20 ml of dH<sub>2</sub>O; 200 ng of  
20 the vector was ligated with 100 ng of 312 bp EcoRI-to-PvuI DNA from pPGK-300 and 100 ng of EcoRI-to-PvuI DNA from pB1. The ligation mix was used to transform E. coli strain 294 to ampicillin resistance. From one of the Ap<sup>R</sup> colonies was obtained pPGK-1500. This plasmid contains the 1500 bp PGK  
25 promoter fragment as an EcoRI-to-EcoRI or HindIII-to-EcoRI piece of DNA.

Construction of expression vector (Figure 6)

30        20  $\mu$ g of pFRL4 was digested with HindIII and BglII then electrophoresed on a 6 percent acrylamide gel. The 230 bp fragment from the TRP1 gene containing part of the structural gene and the 3' untranslated region (28) was isolated by

-26-

electroelution from the gel slice. This is the yeast terminator restriction fragment.

10 µg of pHS94 was restricted with HindIII and EcoRI, run  
5 on a 6 percent acrylamide gel. The 870 bp band representing the HBsAg gene was isolated by electroelution.

3 µg of the HBsAg gene was ligated with 1 µg of the TRP1 "terminator" for 2 hours at room temperature. This solution  
10 was then restricted with EcoRI and BglII and electrophoresed on a 6 percent acrylamide gel. The 1.1 kb band corresponding to 5'-HBsAg/TRP1-3' DNA fragment was isolated by electroelution. 50 µg of pPGK-1500 was restricted with HindIII and EcoRI then electrophoresed on a 6 percent acrylamide gel. The 1.5 kbp PGK  
15 promoter fragment was isolated by electroelution. 10 µg of pCV13 was restricted with HindIII and BamHI then electrophoresed on a 1 percent agarose gel. The large vector fragment was isolated by electroelution. 0.9 µg of pCV13 (HindIII to BamHI), 150 ng of HindIII to EcoRI PGK promoter  
20 fragment, and 100 ng of EcoRI to BglII HBsAg/TRP1 fusion were ligated for 12 hours at 16°C and then used to transform E. coli strain 294 to ampicillin resistance. Miniscreen analysis of a number of transformants indicated that some colonies contained the proper vector construction with promoter-HBsAg structural  
25 gene-TRP1 terminator. Several of these plasmids were used to transform yeast to  $\text{Leu}^+$ .

#### Transformation of yeast and assay for HBsAg

30 Yeast strain XY610-8C was grown in YPD (29), prepared for transformation using standard procedures (20, 21), and transformed to leucine prototrophy( $\text{Leu}^+$ ) using plasmid pCV13 or

-27-

pYeHBs on minimal YNB(-leu) (See Strains and Media).

Transformant colonies were prepared for HBsAg radioimmune assay (Abbott Labs) as follows:

- 5       (1) Grow 10 mls of yeast in YNB-leucine at 30°C with aeration to an absorbance at 660 mμ of 1.0.
- (2) Spin culture 5 min at 5000 xg. Discard supernatant.
- 10       (3) Resuspend cells in 500 μl of PBS (20mM sodium phosphate at pH = 7 plus 0.14 M NaCl), add 1.5 gram sterile glass beads (.45-.50 mm) and vortex 5 min (keeping cold by putting on ice intermittently).
- 15       (4) Spin cell extract 5,000 kg for 3 min at 4°C. Use 200 μl of cell extract for standard radioimmune assay. Cell extract was diluted using PBS.

Evidence for HBsAg Expression in Yeast by pYeHBs

- 20       pYeHBs and pCV13 were used to transform yeast strain XV610-8C to leucine prototrophy in YNB-leu minimal media. The presence of the plasmid was verified by growing the yeast on plates with no leucine selection (YPD) to colonies followed by
- 25       replating to YNB(-leucine) plates (2 percent agar). Fifty to 60 percent of the colonies that grew on YEPD grew on YNB-leu demonstrating that 50-60 percent of yeast contained pCV13 or pYeHBs. It should be noted that a Leu<sup>+</sup> revertant would show growth of all colonies on YNB-leu. pCV13 stability in the
- 30       yeast was no greater than pYeHBs, suggesting that the production of HBsAg (as discussed infra.) does not put pressure on cells to restrict copy number.

Transformant yeast were grown in liquid leucine selection

-28-

media (YNB-leu) then broken open by vortexing with a glass bead suspension (infra.). A radioimmune assay was used to assess HBsAg production in the cleared yeast extract. The 22nm HBsAg particle is roughly 1000 times more antigenic than the HBsAg monomers alone and we used antibody prepared against this particle. The RIA on the yeast extract indicates the production of HBsAg from pYeHBs in yeast. [pCV13 transformed yeast extracts produce no HBsAg antigen material.]

10     Characterization of HBsAg In Yeast 1) 200  $\mu$ l of yeast extract prepared as described above was layered on top of a 5 ml linear density gradient consisting of 5 - 20 percent sucrose (w/v) in 20 mM Tris-HCl (pH 7.4), 0.5 mM EDTA, and 0.5M NaCl then centrifuged in a SW50.1 rotor at 45, 000 rpm for 2 hours.

15     Fractions were collected and assayed for HBsAg by radioimmune assay.

2) 200  $\mu$ l of extract from the same source as above was layered on top of a 5 ml solution containing 20mM Tris-HCl (pH 7.4), 0.5mM EDTA, and CsCl (density 1.2g/cc) then centrifuged in a SW50.1 rotor at 45,000 rpm for 70 hours. HBsAg was assayed as described above and the density of CsCl was determined by recording the refractive index of each gradient fraction.

25

Hepatitis surface antigen is synthesized and secreted from liver cells as a particle (22 nm particle). In the construction described above, only the coding region representing the mature structural gene plus some 3' untranslated sequences were included. We assessed the particulate nature of the hepatitis surface antigen monomer within the yeast cell. To this end, aliquots of a yeast cell

30

-29-

extract containing HBsAg were subjected to sedimentation velocity and sedimentation equilibrium analysis. As shown in Figure 7, the hepatitis surface antigen synthesized in yeast cell has a sedimentation rate that is virtually identical to  
5 that of the "22 nm particle" form of HBsAg obtained from a cell line (PLCWI11) secreting authentic 22 nm particles.

HBsAg synthesized in yeast has a buoyant density of 1.18 g/cm<sup>3</sup> as determined by sedimentation equilibrium analysis.  
10 This value is slightly lower than that of HBsAG synthesized in the infected liver cell.

#### Vaccine Preparation

15 Vaccines incorporating the HBsAg produced as herein described, can be prepared according to known methods, wherein said HBsAg is combined in admixture with a suitable vehicle. Suitable vehicles include, for example, saline solutions, various known adjuvants, or other  
20 additives recognized in the art for use in compositions applied to prevent viral infections. Such vaccines will contain an effective amount of the HBsAg hereof and a suitable amount of vehicle in order to prepare a vaccine useful for effective administration to the host. Attention is also directed to New  
25 Trer is and Developments in Vaccines, Editors: A. Voller and H. Friedman, University Park Press, Baltimore, 1978, which is hereby incorporated by reference, for further background details on the preparation of vaccines.

Bibliography

1. Broach, J. R., Strathern, J. N., and Hicks, J. B. Gene 8, 121-133 (1979).
2. Ratzkin, B., and Carbon, J. Proc. Natl. Acad. Sci. U.S.A. 74, 487-491 (1977).
3. Chinault, A. C., and Carbon, J. Gene 5 111-126 (1979).
4. Hinnen, A., Hicks, J. B., and Fink, G. R. Proc. Natl. Acad. Sci. U.S.A. 75, 1929-1933 (1978).
5. Hitzeman, R. A., Clarke, L., and Carbon, J. J. Biol. Chem. 255, 12073 (1980).
6. Hess, B., Boiteux, A., and Kruger, J. Adv. Enzyme Regul. 7, 143-167 (1968).
7. Holland, J. J., and Holland, J. P. Biochemistry 17, 4900-4907 (1978).
8. Bostian, K. A., Lemire, J. M., Cannon, L. E., and Halvorson, H. O. Proc. Natl. Acad. Sci. U.S.A. 77, 4504-4508 (1980).
9. Abstracts of papers presented at the 1981 meeting on The Molecular Biology of Yeast (August 11- August 16, 1981) Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
10. Chambon, P. Ann. Rev. Biochem. 44, 613-638 (1975).

11. Goeddel, D. V., Shepard, H. M., Yelverton, E., Leung, D.,  
and Crea, R. Nucleic Acids Research 8, 4057-4073 (1980).
12. No reference.
13. Goeddel, D. V. et. al. Nature 287 411-416 (1980).
14. P. Valenzuela, et. al. Nature, 280, 815-819. (1979).
15. P. Charnay et. al. Proc. Natl. Acad. Sci. (U.S.A.) 76,  
2222-2226 (1979).
16. H. Jacobsen et. al. Eur. J. Biochem. 45, 623. (1974).
17. Clarke, L., and Carbon, J. Cell 9, 91-99 (1976).
18. Davis, R. W., Thomas, M. Cameron, J., St. John, T. P.,  
Scherer, S., and Padgett, R. A. Methods in Enzymology 65,  
404-411.
19. Clark, L., and Carbon, J. Proc. Natl. Acad. Sci. U.S.A. 72,  
4361-4365 (1975).
20. Beggs, J. D. Nature 275, 104-109 (1978).
21. Hinnen, A., Hicks, J. B., and Fink, G. R. Proc. Natl. Acad. Sci. U.S.A. 75, 1929-1933 (1978).
22. Birnboim, H. C., and Poly, J. Nucleic Acids Res. 7,  
1513-1523.



23. Bachman, K., Ptashne, M., and Gilbert, W. Proc. Natl. Acad. Sci. U.S.A. 73, 4174-4178 (1976).
24. Miller, J. H. Experiments in Molecular Genetics, pp. 431-433, Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y.
25. Maxam, A. M., and Gilbert, W. Methods in Enzymol. 65, 490-565 (1980).
26. Crea, R. and Horn, T. Nucleic Acids Res. 8, 2331-2348 (1980).
27. Bolivar, F., Rodriguez, R. L. Green, P. Y., Betlach, M. C., Heyneker, H. L., Boyer, H. W., Crosa, Y. H., and Falkow, S. Gene 2, 95-113 (1977).
28. Tschumper, G., and Carbon J. Gene 10, 157-166 (1980).
29. Laboratory Manual for a course Methods in Yeast Genetics  
Cold Spring Harbor Laboratory, Sherman, Fink, and Hicks,  
Cold Spring Harbor, New York.

Claims


1. A DNA expression vector capable of replication and phenotypic selection in yeast host strain comprising a  
5 promoter compatible with a yeast host strain and a DNA sequence encoding hepatitis B surface antigen, said sequence being positioned together with translational start and stop signals in said vector under control of said promoter such that in a transformant yeast strain it is  
10 expressed to produce hepatitis B surface antigen in discrete particle form.
2. The plasmid pYeHBs.
- 15 3. A yeast strain transformed with the DNA expression vector according to Claim 1 or the plasmid according to claim 2.
4. The yeast strain according to Claim 3 obtained by transforming a leu2 auxotrophic yeast strain.  
20
5. The yeast strain according to Claim 3 obtained by  
25 transforming strain XV610-8C.
6. A fermentation culture comprising a transformed yeast according to Claim 3, 4 or 5.
- 30 7. A method of producing hepatitis B surface antigen in particle form suitable for use in conferring immunogenicity to hepatitis B virus in a susceptible human which comprises:

-34-

- a) providing a DNA transfer vector capable of replication and phenotypic selection in yeast host strains,
  - b) providing a DNA fragment comprising a promoter  
5 compatible with a yeast host strain,
  - c) providing a DNA fragment encoding hepatitis B surface antigen,
  - 10 d) assembling the fragments of steps a), b) and c) together with appropriately positioned translational start and stop signals to form a replicable expression vector characterized in that said sequence of step c) is under control of said promoter such that it is  
15 expressible to produce discrete hepatitis B surface antigen,
  - e) transforming a yeast strain with the vector of step d),
  - 20 f) allowing the yeast transformant to grow until said hepatitis B surface antigen is produced therein, and
  - g) recovering said hepatitis B surface antigen in  
25 discrete particle form.
8. The method according to Claim 7 wherein the DNA sequence of step c) comprises, in order from the 5' end of its coding strand, an ATG translational start codon, the nucleotides  
30 encoding hepatitis B surface antigen of the hepatitis B genome, and translational stop signal(s).

9. The method according to Claim 7 or 8 wherein the yeast strain of step e) is XV610-8C.
10. The method according to any one of Claims 7 to 9 wherein  
5 the promoter of step b) is derived from the yeast PGK promoter region.
11. The use of hepatitis B surface antigen, produced by the method according to Claim 8, for conferring immunogenicity  
10 to hepatitis B virus in a susceptible human or for preparing a vaccine therefor.

FIG. A



THE INSERTION OF AN EcoRI SITE IN THE 5' FLANKING DNA  
OF THE 3-PHOSPHOGLYCERATE GENE OF YEAST




FIG. 1.

DNA SEQUENCE OF THE 5' END  
OF THE YEAST 3-PHOSPHOGLYCERATE KINASE  
STRUCTURAL GENE AND FLANKING DNA

5'-----GATCATAAGGAAGTAATTATCTACTCTTTTACACAAATATATAAACA ATG TCT TTA TCT TCA AAG TTG CTC GTC  
-40 -30 -20 -10 -1 MET SER LEU SER SER LYS LEU LEU VAL

Fig. 2.




FIG. 3.








FIG. 4.








FIG. 7



European Patent  
Office

# EUROPEAN SEARCH REPORT

0073657  
Application number

EP 82 30 4513

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
A	--- EP-A-0 013 828 (BIOGEN N.V.) *Pages 37-43; claims*	1-11	C 12 N 15/00 A 61 K 39/29
A	--- FR-A-2 270 892 (INSTITUT FRANCAIS D'IMMUNOLOGIE)		
A	--- EP-A-0 020 251 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) -----		
			TECHNICAL FIELDS SEARCHED (Int. Cl. 3)
			A 61 K C 12 N
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 30-11-1982	Examiner REMPP G.L.E.
<b>CATEGORY OF CITED DOCUMENTS</b>			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons  & : member of the same patent family, corresponding document	